Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Ixo-vec, a potential one shot therapy for age-related macular degeneration has achieved noninferior results in maintaining best-corrected visual acuity and central subfield thickness.

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.

A panel of eye care specialists share clinical advice and future directions for the treatment of wet AMD.

Dante J. Pieramici, MD; Roger A. Goldberg, MD, MBA; and Lloyd Clark, MD, review novel compounds in development for the treatment of wet AMD.

Dante J. Pieramici, MD, leads the discussion on potential safety issues of anti-VEGF agents and addressing these concerns with patients who have wet AMD.

A panel of eye care specialists review challenges faced with the management of wet AMD when patients are put on an extended treatment regimen.

Dante J. Pieramici, MD, and Lloyd Clark, MD, provide insight on approaching the treatment of wet AMD with intravitreal injections and discuss creating a tailored treatment regimen for patients.

Dante J. Pieramici, MD, leads the discussion on the use of VEGF inhibitors for retinal diseases other than wet AMD.

Dante J. Pieramici, MD, leads the discussion on factors to consider when selecting the optimal therapy for patients with wet AMD.

Lloyd Clark, MD, and Roger A. Goldberg, MD, MBA, share the process for giving injections in the eye for patients who have wet AMD.

A panel of eye care specialists review the 4 currently available anti-VEGF agents available for the treatment of wet AMD.

Roger A. Goldberg, MD, MBA, discusses the evolution of therapy from pre– to post–anti-VEGF agents for patients with wet AMD.

Lloyd Clark, MD, leads the discussion on the goals of therapy for patients with wet AMD and the role of anti-VEGF agents for treatment.

A panel of eye care specialists review tests used in clinical practice to screen patients for wet AMD and comment on the clinical benefit of early intervention in patients.

Lloyd Clark, MD, leads the discussion on the differential diagnosis of wet AMD and the optimal approach to an accurate diagnosis.

Roger A. Goldberg, MD, MBA, and Lloyd Clark, MD, provide insight on initial symptoms patients typically present with in wet AMD.

Dante J. Pieramici, MD, and Lloyd Clark, MD, define age-related macular degeneration (AMD) and highlight the role of antioxidant vitamins in preventing vision loss.